Drugs / DCVax-Direct
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03638765 | Nov 2018 → Dec 2019 | breast cancer, lung cancer, metastatic malignant neoplasm in the brain | Northwest Biotherapeutics | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01882946 | Jun 2013 → Dec 2016 | colorectal cancer, liver cancer, malignant pancreatic neoplasm, melanoma +1 | Northwest Biotherapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCVax-Direct | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01882946 ↗ |
| Modality | Cell therapy | “Autologous, activated dendritic cells” NCT01882946 ↗ |
| Route | Other | “for intratumoral injection” NCT01882946 ↗ |